Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation's filings document the capital structure and public-company reporting for its common stock, 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP), and depositary shares representing interests in its Series B preferred stock on Nasdaq. Recent 8-K disclosures address financial results, Regulation FD materials, material definitive agreements and the completed acquisition of Generation Bio, including supplemental information about legacy assets.
Proxy materials describe annual meeting proposals, shareholder voting procedures and governance matters. For the preferred security, the filing record identifies the registered preferred-stock class and places capital-structure and transaction disclosures in the context of XOMA Royalty's biotechnology royalty aggregation business.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
Bradley Sitko, Chief Investment Officer and director of XOMA Royalty Corp (XOMAP), reported transactions dated 09/19/2025. The filing shows Sitko acquired 6,712 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock; these PSUs vest upon the common stock reaching a specified price and are scheduled to be exercisable by 05/18/2026. Following the reported PSU acquisition, Sitko beneficially owned 23,488 derivative-backed shares and 19,822 common shares by direct ownership. The report also discloses disposals of certain preferred and depositary share instruments and multiple indirect holdings through his 401(k) plan, spouse, and children.
Owen Hughes, who is listed as Chief Executive Officer and a Director of XOMA Royalty Corp, reported transactions dated 09/19/2025. The filing shows acquisition of 35,567 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock and vest upon the common stock reaching a specified price per share. After these derivative and related non‑derivative entries, Mr. Hughes is reported to beneficially own 132,714 shares on a direct basis. The filing also records a disposition of 2,000 Depository Shares of an 8.375% Series B Cumulative security. The form is signed by an attorney‑in‑fact and includes a Power of Attorney exhibit.
Thomas M. Burns, SVP, Finance & CFO of XOMA Royalty Corp (symbol: XOMAP), reported equity activity related to vested performance stock units and subsequent share sales to cover taxes. He was credited with 11,846 common shares from PSUs that vest when the stock reaches a specified price, increasing his direct common-stock holdings to 34,409 shares. Shortly thereafter he sold 4,300 shares at $35.98 and two small blocks of 15 shares each at $36.93 and $36.81, reducing his direct holdings to roughly 30,079 shares.
He also reports 6,130 shares held indirectly through a 401(k) plan and disposal of 2,000 depository shares and 2,000 series A preferred shares. The filing explains the sales were to satisfy tax withholding on PSU settlement, and the PSUs convert one-for-one into common stock with an exercisable date of 05/18/2026.
Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.
XOMA Royalty Corporation (XOMAP) entered into a merger with HilleVax, Inc. under an Agreement and Plan of Merger dated August 4, 2025, after a related tender offer described in an Offer to Purchase dated August 18, 2025. At the Effective Time, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of XOMA, with outstanding HilleVax shares (subject to customary exceptions) cancelled and converted into the right to receive the Offer Price, comprised of a cash amount and a non-transferable Contingent Value Right (CVR).
A Contingent Value Rights Agreement dated September 17, 2025 governs potential cash payments under the CVR, with Broadridge named as rights agent and Dr. Robert Hershberg as initial representative of holders. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corporation completed a merger with Turnstone Biologics Corp. under an Agreement and Plan of Merger dated June 26, 2025, effected by a merger of XOMA's wholly owned subsidiary into Turnstone under Delaware law with no stockholder vote required. At the Effective Time, each outstanding share (subject to limited exceptions) was converted into the right to receive a cash payment equal to the Cash Amount (less tax withholding) and one CVR governed by the Contingent Value Rights Agreement dated August 11, 2025. The CVR entitles holders to potential additional cash payments under specified terms, and the Offer to Purchase and Letter of Transmittal were filed as exhibits to the Schedule TO on July 23, 2025. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corp. reporting person Maricel Perea Montano, Chief Legal Officer and director, was granted 23,450 Performance Stock Units (PSUs) on 08/12/2025. Each PSU converts to one share of XOMA common stock if a specified stock price target is met. The PSUs are shown as acquired with a $0 exercise price and are recorded as 23,450 shares beneficially owned following the award, held in a direct form.
The PSUs become eligible for issuance on 05/16/2026 subject to achieving the stated price condition. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/14/2025. No sale or cash payment is reported; this filing documents a contingent equity award tied to future stock performance.